Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator

Area of Science:

• Virology
• Cardiovascular Physiology
• Pharmacology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19.
• Angiotensin-converting enzyme 2 (ACE2) is the primary receptor for SARS-CoV-2.
• ACE2 regulates the renin-angiotensin system (RAS) and is vital for cardiovascular health.

Purpose of the Study:

• To summarize recent research on the interplay between coronaviruses, ACE2, and RAS.
• To address the therapeutic dilemma of blocking viral entry while preserving ACE2 function.
• To provide guidance for COVID-19 intervention strategies.

Main Methods:

• Literature review and synthesis of current research.
• Proposal of five novel working models for SARS-CoV-2 infection via ACE2.
• Theoretical analysis of anti-renin-angiotensin system (RAS) drug applications.

Main Results:

• Detailed explanation of ACE2-mediated viral entry routes and regulatory mechanisms.
• Identification of five potential functional receptor working modes for SARS-CoV-2.
• Discussion on the implications and controversies surrounding anti-RAS drug use in COVID-19 patients.

Conclusions:

• A deeper understanding of the virus-ACE2-RAS interaction is crucial for effective COVID-19 treatment.
• Novel insights into viral entry mechanisms can inform the development of targeted therapies.
• Careful consideration of anti-RAS drugs is necessary, balancing benefits against potential risks.